EMA confirms positive benefit-risk profile for Novartis' Gilenya, but with label change; updated US label

23 April 2012

Swiss drug major Novartis (NOVN: VX) said on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has confirmed a positive benefit-risk profile of its once-daily oral multiple sclerosis drug Gilenya (fingolimod).

Novartis and the CHMP have agreed to recommended updates to the product information in the European Union in order to provide further guidance to health care providers regarding treatment initiation with Gilenya in MS patients. The changes follow the Article 20 review by the EMA announced in January 2012.

"We believe that Gilenya is a valuable treatment option for many patients with relapsing remitting MS, and we welcome the confirmation of the positive benefit-risk profile of the drug which also supports our continued belief of the blockbuster potential of Gilenya," said David Epstein, division head of Novartis Pharmaceuticals, adding: "MS is a devastating chronic disease that affects more than 2.1 million people worldwide, and patients need effective treatment options."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK